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LETTERS
Lyme Borreliosis
and Borrelia 
spielmanii
To the Editor: A report on erythe-
ma migrans (EM) caused by Borrelia
spielmanii in a recent issue of
Emerging Infectious Diseases (1) was
a stimulus for a review of data on this
Borrelia species in patients with early
Lyme borreliosis (LB). We report a
patient with EM, examined at our LB
outpatient clinic, from whom B. spiel-
manii was isolated from the skin
lesion. The presence of this species
was ascertained by using a 5S–23S
spacer amplicon after digestion with
MseI and demonstration of fragments
having sizes typical for B. spielmanii
(106, 68, and 51 bp) (2).
A 69-year-old woman was exam-
ined on October 30, 1996, for a skin
lesion on her left thigh. Her medical
history indicated arterial hyperten-
sion, intermittent pain in the cervical
and lumbar region due to spondylosis,
frequent headaches and myalgias, and
treatment of typical EM skin lesions
at our LB outpatient clinic in 1992
and 1994; the latter lesions were cul-
ture positive for Borrelia. Fourteen
days before examination, she noticed
a small area of redness, accompanied
by mild local itching, burning, and
pain on her left knee. On examination,
a 24 × 20–cm ringlike lesion was
found on her left thigh. Basic blood
tests did not show abnormal results,
and a serum sample was negative for
borrelial antibodies (immunofluores-
cence test using a B. afzelii skin iso-
late as antigen) (3). However, B. spiel-
manii was isolated from an EM skin
biopsy specimen. The patient was
treated with amoxicillin, 500 mg 3
times a day for 15 days. The skin
lesion disappeared within 3 weeks,
and a culture of a repeat skin biopsy
specimen was negative for Borrelia 2
months after the first biopsy. Her clin-
ical course during a 1-year follow-up
was uneventful.
B. spielmanii was detected in the
patient by a general approach we have
used for several years. In all consent-
ing patients, a skin specimen from an
EM lesion is cultured for borreliae in
modified Kelly medium before and, in
case of a positive result, ≈2 months
after antimicrobial drug treatment is
started. Isolated strains are typed by
using the 5S–23S spacer amplicon.
The findings in this report are gen-
erally consistent with those in other
reports of adult patients with EM
(4–8). One difference was that the
patient did not report a tick bite at the
site of the EM. Approximately two
thirds of our patients with EM
recalled a tick bite and ≈10% of
patients treated for early LB had pre-
viously had EM (4–8). 
Previous reports indicate several
differences in patients with EM caused
by B. burgdorferi and B. afzelii (7) and
patients with EM caused by B. afzelii
and B. garinii (8,9). Some of the find-
ings in our patient are unusual and
rarely found in those with early LB.
However, the small number of patients
infected with B. spielmanii (1 reported
herein and 4 previously reported) does
not allow any reliable conclusion to be
made on differences in clinical mani-
festations of LB caused by B. spiel-
manii compared with those of other
species.
Our results corroborate previous
findings that B. spielmanii is a cause
of LB in Europe. Thus, in addition to
the Netherlands (2), Germany (10),
and Hungary (1), LB caused by B.
spielmanii is also present in Slovenia.
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